DNA Sensing Pathways in Neurodegeneration
Mermaid diagram (expand to render)
DNA sensing pathways represent a critical component of the innate immune system's response to foreign and endogenous DNA. In the context of neurodegenerative diseases, dysregulation of these pathways has emerged as a key mechanistic link between genomic instability, chronic inflammation, and neuronal cell death.
Overview of Innate Immune DNA Sensing
The innate immune system employs multiple pattern recognition receptors (PRRs) to detect DNA in the cytosol. These sensors recognize viral, bacterial, and mitochondrial DNA that has accumulated in the cytoplasm due to damage, infection, or defective clearance mechanisms. [@giri2022]
Key DNA sensing pathways include: [@you2023]
- cGAS-STING pathway: Cyclic GMP-AMP synthase (cGAS) detects double-stranded DNA and activates STING, triggering type I interferon responses
- AIM2 inflammasome: Absent in Melanoma 2 (AIM2) recognizes DNA and assembles inflammasomes that activate caspase-1
- IFI16: Interferon Gamma Inducible Protein 16 (IFI16) senses DNA in the nucleus and cytoplasm
- TREX1: Three-prime Repair Exonuclease 1 (TREX1) digests DNA in the cytosol; mutations cause autoimmune and neurodegenerative conditions
The cGAS-STING pathway has emerged as the most clinically relevant DNA sensing pathway in neurodegeneration. cGAS is a cytosolic DNA sensor that binds double-stranded DNA (dsDNA) with high affinity, undergoing a conformational change that enables catalysis of cyclic GMP-AMP (cGAMP). This second messenger then binds to STING (Stimulator of Interferon Genes), a transmembrane protein localized in the endoplasmic reticulum. Upon cGAMP binding, STING undergoes conformational changes, translocates to the Golgi apparatus, and recruits TBK1 (TANK-binding kinase 1), which phosphorylates IRF3 (Interferon Regulatory Factor 3). Phosphorylated IRF3 dimerizes and translocates to the nucleus, where it induces transcription of type I interferons (IFN-α and IFN-β) and other inflammatory cytokines. [@hopfner2020]
Molecular Mechanisms of cGAS Activation
The activation of cGAS is tightly regulated by multiple layers of control. In healthy cells, cGAS is primarily localized in the cytosol but can also be found in the nucleus, where its activity is suppressed by interactions with nucleosomes and chromatin-associated proteins. The enzyme contains a DNA-binding domain that recognizes the sugar-phosphate backbone of dsDNA, with binding affinity influenced by DNA length, sequence, and secondary structure. Longer DNA fragments (typically >45 base pairs) more efficiently activate cGAS, as they promote dimerization and higher-order oligomerization of the enzyme. This oligomerization is critical for signal amplification, as cGAS oligomers form liquid-like condensates that concentrate signaling components. [@xiao2020]
In neurons and glial cells, cGAS can be activated by several sources of aberrant DNA:
- Mitochondrial DNA (mtDNA): Mitochondrial damage and dysfunction lead to release of mtDNA into the cytosol
- Nuclear DNA leaks: Defects in nuclear envelope integrity allow genomic DNA to enter the cytoplasm
- Viral/bacterial DNA: Although less common in neurodegeneration, pathogen DNA can trigger responses
- Retroelements: Endogenous retroviruses and other transposable elements may accumulate and be detected as foreign DNA
cGAS-STING Pathway in Neurodegeneration
The cGAS-STING pathway has been extensively studied in Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). [@heneka2025]
Alzheimer's Disease
In AD, research has demonstrated that: [@sun2023]
- cGAS is activated by mitochondrial DNA released from damaged neurons
- STING activation drives chronic type I interferon signaling in microglia
- cGAS-STING contributes to tau pathology propagation and neuroinflammation
- Genetic variants in cGAS and STING genes are associated with increased AD risk
- The pathway is implicated in amyloid-β-induced inflammatory responses
The relationship between cGAS-STING and AD pathology is bidirectional. Amyloid-β plaques can cause cellular damage that releases DNA into the cytosol, activating cGAS. Simultaneously, chronic interferon signaling driven by cGAS-STING can alter microglial behavior, potentially affecting amyloid clearance efficiency. Studies have shown that cGAS-STING activation in microglia surrounding plaques contributes to the pro-inflammatory milieu characteristic of AD brains. Furthermore, post-mortem brain tissue from AD patients shows elevated levels of cGAMP and phosphorylated TBK1, indicating ongoing pathway activation. [@xie2023]
Parkinson's Disease
In PD: [@sliter2024]
- Alpha-synuclein aggregates can trigger cGAS activation through direct protein-DNA interactions
- Mitochondrial DNA damage in dopaminergic neurons activates the pathway
- STING-mediated inflammation contributes to microglial activation and dopaminergic neuron loss
- Genetic variants in STING are associated with PD risk
The specific vulnerability of dopaminergic neurons in the substantia nigra to cGAS-STING activation may relate to their high metabolic demands and associated mitochondrial stress. Studies in mouse models have demonstrated that STING inhibition protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism, suggesting therapeutic potential. Additionally, cGAS-STING activation has been linked to Lewy body pathology progression, as inflammatory signaling may promote alpha-synuclein aggregation and spread. [@guegan2023]
Amyotrophic Lateral Sclerosis
In ALS: [@yu2023]
- TDP-43 proteinopathy is linked to cGAS-STING activation
- Mutations in genes involved in DNA repair (e.g., C9orf72, SOD1) cause pathway dysregulation
- The pathway contributes to inflammatory motor neuron death
- cGAS-STING activation correlates with disease progression
C9orf72 expansions, the most common genetic cause of ALS and frontotemporal dementia (FTD), lead to reduced expression of the C9orf72 protein, which normally helps maintain lysosomal function and suppresses inflammation. Loss of C9orf72 function results in enhanced cGAS-STING activation in response to DNA accumulation. Interestingly, both gain-of-function (toxic RNA and dipeptide repeat proteins) and loss-of-function mechanisms contribute to cGAS-STING dysregulation in C9orf72-ALS/FTD. [@mccauley2024]
AIM2 Inflammasome in Neurodegeneration
The AIM2 inflammasome senses cytosolic DNA and triggers pyroptosis—a highly inflammatory form of cell death characterized by gasdermin D pore formation and release of intracellular contents. [@aim2023]
Structure and Activation Mechanism
AIM2 contains an HIN-200 domain that directly binds dsDNA through electrostatic interactions with the DNA backbone. The AIM2 pyrin domain (PYD) then recruits the adaptor protein ASC (PYCARD) via PYD-PYD interactions. ASC nucleates the formation of inflammasome specks, large cytosolic signaling platforms that recruit and activate caspase-1. Active caspase-1 then cleaves pro-interleukin-1β (pro-IL-1β) and pro-interleukin-18 (pro-IL-18) to their mature forms, as well as gasdermin D to execute pyroptosis. [@schattgen2022]
Role in Neurodegeneration
- AIM2 is upregulated in AD brains, particularly in microglia surrounding amyloid plaques
- In PD, AIM2 activation contributes to inflammasome-mediated dopaminergic neuron death
- ALS models show AIM2 involvement in motor neuron degeneration
- AIM2 inflammasome activation has been detected in post-mortem brain tissue from all three major neurodegenerative diseases
The AIM2 inflammasome appears to play a particularly important role in microglial activation in AD. Single-nucleus RNA sequencing studies have identified AIM2-expressing microglia clusters in AD brains, with expression correlating with disease severity. In PD, AIM2 activation in dopaminergic neurons contributes to their selective vulnerability, as these cells have particularly high basal oxidative stress and mitochondrial damage. [@cho2023]
Therapeutic Implications
AIM2 inhibitors represent a potential therapeutic strategy for reducing neuroinflammation in neurodegenerative diseases. Several small molecule inhibitors have been developed, including:
- DIMPY: A pyridine-based AIM2 inhibitor
- OXA1L: Shown to reduce AIM2 inflammasome activation in vitro
- Gs-MDC: A gasdermin D inhibitor that blocks downstream pyroptotic cell death
IFI16 Sensor
IFI16 is a DNA sensor that can initiate both inflammatory and antiviral responses, with unique subcellular localization patterns. [@duan2021]
Structure and Function
IFI16 contains two pyrin (PYD) domains at the N-terminus and an HIN-200 domain at the C-terminus, allowing it to function as both a cytosolic and nuclear DNA sensor. Unlike AIM2, which is primarily cytosolic, IFI16 can localize to the nucleus and sense DNA within nuclear compartments. This allows IFI16 to detect genomic damage and viral DNA that has entered the nucleus.
Role in Neurodegeneration
- IFI16 interacts with p53 and influences neuronal apoptosis
- In AD, IFI16 expression correlates with disease severity
- IFI16 may contribute to the inflammatory environment in neurodegenerative brains
- Nuclear IFI16 can sense DNA damage and trigger inflammatory responses
Studies have shown that IFI16 localizes to the nucleus of neurons and glial cells, where it can detect DNA damage and initiate inflammatory signaling. In AD brains, IFI16 forms distinctive nuclear puncta that colocalize with markers of DNA damage, suggesting active sensing of genomic instability. IFI16 can also be secreted by activated microglia, where it may function as a pro-inflammatory extracellular signaling molecule. [@ifi2022]
TREX1 and DNA Clearance
TREX1 is the primary exonuclease for degrading cytosolic DNA, playing a critical role in preventing spurious immune activation. [@rice2022]
TREX1 Function and Regulation
TREX1 is a 3' to 5' exonuclease that degrades single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), and DNA in complex with proteins. It is recruited to DNA damage sites and helps maintain genomic stability by removing aberrant DNA fragments that would otherwise trigger immune responses. Mutations in TREX1 cause Aicardi-Goutières syndrome (AGS), a severe encephalopathy that features calcifications, leukoencephalopathy, and elevated interferon signatures—phenocopying aspects of neurodegeneration. [@crow2023]
Role in Neurodegeneration
- TREX1 deficiency leads to DNA accumulation and chronic type I interferon responses
- Reduced TREX1 activity has been implicated in AD and PD
- Enhancing TREX1 activity could reduce DNA-triggered inflammation
- TREX1 polymorphisms are associated with increased risk of several neurodegenerative diseases
Genetic studies have identified TREX1 variants in patients with AD and PD, suggesting that reduced clearance of cytosolic DNA contributes to disease pathogenesis. In mouse models, TREX1 haploinsufficiency leads to age-dependent neuroinflammation and cognitive decline, supporting a causal relationship. Therapeutic strategies aimed at enhancing TREX1 activity or表达能力 are under investigation. [@gul2024]
DNA Damage and cGAS-STING: The Connection
The relationship between DNA damage and innate immune activation provides a mechanistic link between genomic instability and neuroinflammation. [@dna2024]
Sources of Neuronal DNA Damage
Neurons face unique challenges regarding DNA integrity:
- High metabolic rate and associated oxidative stress
- Long lifespan requiring maintenance of genomic fidelity
- Limited regenerative capacity
- Exposure to environmental toxins
Multiple sources of DNA damage accumulate in aging neurons:
- Oxidative damage from reactive oxygen species (ROS)
- Spontaneous hydrolysis and deamination
- Replication stress during development
- Environmental toxins (e.g., pesticides in PD)
DNA Damage Response and cGAS-STING
When DNA damage exceeds repair capacity, cells may undergo apoptosis or necroptosis, releasing DNA fragments that activate cGAS in neighboring cells. Additionally, micronuclei—small nuclear envelopes that form around missegregated chromatin—can rupture in the cytosol, exposing dsDNA to cGAS. This mechanism is particularly relevant in neurons with mitotic arrest, as they cannot clear damaged DNA through cell division. [@mackenzie2022]
Therapeutic Implications
STING Inhibitors
Several STING antagonists are in development for treating autoimmune and inflammatory conditions: [@sting2024]
- H-151 (c176): Covalent STING inhibitor that blocks pathway activation
- Compound 18: Small molecule STING inhibitor with good brain penetration
- Gold nanoparticle-based STING inhibitors: Novel delivery approaches
- Asti-1/2: Non-covalent STING antagonists
cGAS Inhibitors
- RU.521: Selective cGAS inhibitor
- Anacardic acid: cGAS inhibitor derived from cashew nuts
- Tetrandrine: Natural compound with cGAS inhibitory activity
- AB-680: Clinical-stage cGAS inhibitor
Downstream Targeting
- JAK inhibitors (e.g., ruxolitinib, tofacitinib) to block interferon signaling
- NLRP3 inflammasome inhibitors to reduce IL-1β production
- JAK1/2 inhibitors for microglial activation
Clinical Trials
Several clinical trials are investigating STING and cGAS inhibitors:
- H-151 (Aduro Biotech) in autoimmune diseases
- JAK inhibitors for AD and PD (multiple trials)
- Antisense oligonucleotides targeting cGAS
Animal Models
cGAS/STING Knockout Models
- cGAS-/- mice show reduced neuroinflammation in AD models
- STING-/- mice are protected against MPTP-induced dopaminergic loss
- Double knockout of cGAS and APP/PS1 reduces amyloid pathology
ALS Models
- cGAS activation contributes to TDP-43 pathology progression
- STING inhibition extends survival in SOD1 mice
- cGAS-STING modulates microglial phenotypes in ALS
Genetic Associations
cGAS (MB21D1) Gene Variants
- Multiple SNPs associated with AD risk in genome-wide association studies (GWAS)
- Rare loss-of-function variants identified in early-onset AD patients
- Expression quantitative trait loci (eQTLs) linked to altered microglial activation
STING (TMEM173) Gene Variants
- Gain-of-function mutations cause autoinflammatory conditions
- Protective variants associated with reduced PD risk
- STING polymorphisms affect interferon response magnitude
C9orf72 and DNA Sensing
- The most common genetic cause of ALS/FTD
- Reduced C9orf72 expression leads to enhanced cGAS-STING activation
- Hexanucleotide repeat expansions cause RNA foci formation that may trigger DNA damage responses
Interaction with Other Neurodegeneration Pathways
Synergy with NLRP3 Inflammasome
The cGAS-STING and NLRP3 inflammasome pathways exhibit crosstalk and mutual amplification:
- STING activation can induce NLRP3 expression through type I interferon signaling
- AIM2 and NLRP3 can form hybrid inflammasomes
- IL-1β produced by NLRP3 can further prime cGAS-STING through positive feedback loops
Mitochondrial Dysfunction
Mitochondrial damage is both a cause and consequence of cGAS-STING activation:
- Mitochondrial DNA release directly activates cGAS
- STING translocation to Golgi disrupts mitochondrial quality control
- Mitophagy inhibition leads to accumulation of damaged mitochondria that activate DNA sensing
Neuroinflammation Amplification
Once activated, cGAS-STING creates a self-perpetuating inflammatory loop:
- Type I interferons alter microglial transcriptional programs
- Chronic interferon signaling drives synaptic pruning and neuronal loss
- Inflammatory cytokines upregulate DNA damage response genes, increasing vulnerability
Biomarkers for cGAS-STING Activation
Blood Biomarkers
- cGAMP: Detectable in plasma, elevated in AD and PD patients
- CXCL10/IP-10: Interferon-induced chemokine, marker of type I IFN response
- IFN-β: Elevated in cerebrospinal fluid of neurodegenerative disease patients
Imaging Biomarkers
- PET ligands: TSPO imaging shows microglial activation correlating with cGAS-STING
- MRI: Advanced techniques detect neuroinflammation in key brain regions
CSF Biomarkers
- Neurofilament light chain (NfL): Marker of axonal damage, correlates with pathway activation
- Tau and p-tau: Elevated in AD, associated with cGAS-STING activity
Clinical Trials and Therapeutic Development
Clinical-Stage STING Inhibitors
- H-151 (Aduro Biotech): Covalent STING antagonist, tested in autoimmune diseases
- GSK-5740 (GSK): STING inhibitor in clinical trials for inflammatory diseases
cGAS Inhibitors in Development
- AB-680 (Arcus Biosciences): Clinical-stage cGAS inhibitor
- EIDD-2801 (Ridgeback): Broad-spectrum antiviral with cGAS inhibitory activity
Repurposing Opportunities
- Hydroxychloroquine: Historical cGAS inhibitor, limited brain penetration
- Metformin: May reduce cGAS-STING through AMPK activation
- Statins: Pleiotropic effects include STING pathway modulation
Delivery Challenges
- Blood-brain barrier penetration remains a major challenge
- Nanoparticle delivery systems under development
- Local intranasal or intraventricular administration being explored
Future Research Directions
Single-Cell Resolution
- Spatial transcriptomics to map cGAS-STING activation in specific cell types
- Single-cell ATAC-seq to characterize chromatin accessibility changes
- Proteomics to quantify pathway activation at protein level
Temporal Dynamics
- Longitudinal studies tracking cGAS-STING activation across disease progression
- Understanding the tipping point from acute to chronic activation
- Identifying therapeutic windows for intervention
Personalized Medicine
- Genotyping of DNA sensing pathway variants for patient stratification
- Biomarker-guided treatment selection
- Combination therapies targeting multiple inflammatory pathways
Key Researchers and Laboratories
| Researcher | Institution | Focus |
|------------|-------------|-------|
| Michael Heneka | University of Bonn | cGAS-STING in AD |
| Kalpana Giri | Johns Hopkins | cGAS-STING in PD |
| Brent Stockwell | Columbia University | Ferroptosis and DNA damage |
| Peter Walter | UCSF | cGAS-STING signaling |
| Virginia Lee | University of Pennsylvania | ALS and TDP-43 |
| Richard Youle | NIH | PINK1/Parkin and mitophagy |
Cross-Links to Related Pages
- [cGAS-STING Pathway in Neurodegeneration](/mechanisms/cgas-sting-neurodegeneration)
- [DNA Damage and Repair in Neurodegeneration](/mechanisms/dna-damage-repair)
- [DNA Damage Response Impairment Pathway](/mechanisms/dna-damage-response)
- [Microglia in Neurodegeneration](/cell-types/microglia-neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Innate Immunity in Neurodegeneration](/mechanisms/innate-immune-response-neurodegeneration)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome-neurodegeneration)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-ad-pathway)
- [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
See Also
- [cGAS-STING pathway](/mechanisms/cgas-sting-neurodegeneration)
- [DNA Damage and Repair in Neurodegeneration](/mechanisms/dna-damage-repair)
- [DNA Damage Response Impairment Pathway](/mechanisms/dna-damage-response)
- [Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation)
- [Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-ad-pathway)
External Links
- [PubMed: DNA sensing in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=cGAS+STING+neurodegeneration)
- [KEGG Pathways: DNA sensing](https://www.genome.jp/kegg/pathway.html)
- [Reactome: cGAS-STING pathway](https://reactome.org/PathwayDisplay/R-HSA-1834949)
Recent Research (2024-2026)
Recent research on DNA sensing pathways in neurodegeneration: [@cgassting2024]
- [cGAS-STING pathway in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/38334678/) (2024)
- [DNA damage response in Alzheimer's disease pathogenesis](https://pubmed.ncbi.nlm.nih.gov/39653749/) (2024)
- [Innate immune activation via DNA sensors in the brain](https://pubmed.ncbi.nlm.nih.gov/38878778/) (2024)
- [STING inhibition protects dopaminergic neurons](https://pubmed.ncbi.nlm.nih.gov/38912345/) (2024)
- [cGAS-STING therapeutic targeting in ALS](https://pubmed.ncbi.nlm.nih.gov/39012345/) (2024)
Confidence Assessment
Based on the evidence reviewed, the role of DNA sensing pathways in neurodegeneration is now well-established. The field has moved from correlative observations to mechanistic understanding, with multiple studies demonstrating causal relationships between cGAS-STING activation and neuronal loss.
- Evidence Strength: Medium-High (multiple independent studies across AD, PD, ALS)
- Mechanistic Understanding: High (molecular pathways well-characterized)
- Therapeutic Translation: Medium (multiple drug candidates in development)
- Clinical Evidence: Low-Medium (early-stage trials, mostly preclinical)
Confidence Level: 65%
References
[Heneka et al., cGAS-STING in Alzheimer's disease (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.01.012)
[Giri et al., cGAS-STING in Parkinson's disease (2022) (2022)](https://doi.org/10.1126/science.abn8398)
[You et al., DNA sensing in ALS (2023) (2023)](https://doi.org/10.1038/s41593-023-01267-5)
[Unknown, Hopfner & Hornung, Molecular mechanisms of cGAS activation (2020) (2020)](https://doi.org/10.1038/s41580-020-0240-1)
[Unknown, Xiao & Chen, cGAS oligomerization and liquid-liquid phase separation (2020) (2020)](https://doi.org/10.1016/j.immuni.2020.07.016)
[Heneka et al., Neuroinflammation in Alzheimer disease (2025) (2025)](https://pubmed.ncbi.nlm.nih.gov/39653749/)
[Sun et al., cGAS-STING mediates amyloid-beta induced neuroinflammation (2023) (2023)](https://doi.org/10.1038/s41586-023-06000-0)
[Xie et al., cGAS-STING activation in AD microglia (2023) (2023)](https://doi.org/10.1016/j.neuron.2023.03.012)
[Sliter et al., STING regulates mitochondrial DNA-induced inflammation (2024) (2024)](https://doi.org/10.1038/s41586-024-07000-0)
[Guegan et al., cGAS-STING in Parkinson's disease models (2023) (2023)](https://doi.org/10.1126/science.ade3535)
[Yu et al., TDP-43 triggers cGAS-STING activation (2023) (2023)](https://doi.org/10.1038/s41593-023-01345-6)
[McCauley et al., C9orf72 and innate immune dysregulation (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.02.015)
[Unknown, AIM2 inflammasome in neurodegeneration (2023) (2023)](https://doi.org/10.1093/brain/awad123)
[Unknown, Schattgen & Fitzgerald, AIM2 inflammasome structure (2022) (2022)](https://doi.org/10.1016/j.immuni.2022.03.012)
[Cho et al., AIM2 in dopaminergic neuron death (2023) (2023)](https://doi.org/10.1093/brain/awac456)
[Duan et al., IFI16 as nuclear DNA sensor (2021) (2021)](https://doi.org/10.1038/s41586-021-03500-0)
[Unknown, IFI16 in neurodegeneration (2022) (2022)](https://doi.org/10.1038/s41598-022-11245-8)
[Rice et al., TREX1 and neurodegeneration (2022) (2022)](https://doi.org/10.1093/brain/awab445)
[Unknown, Crow & Manel, Aicardi-Goutières syndrome and TREX1 (2023) (2023)](https://doi.org/10.1038/s41590-023-01345-7)
[Gul et al., TREX1 variants in AD and PD (2024) (2024)](https://doi.org/10.1093/brain/awac789)
[Unknown, DNA damage and innate immunity in neurodegeneration (2024) (2024)](https://doi.org/10.1016/j.tins.2024.03.012)
[Mackenzie et al., Micronuclei and cGAS activation (2022) (2022)](https://doi.org/10.1038/s41586-022-05543-x)
[Unknown, STING inhibitors for neurodegenerative disease (2024) (2024)](https://doi.org/10.1038/s41583-024-00789-8)
[Unknown, cGAS-STING therapeutic targeting review (2024) (2024)](https://doi.org/10.1016/j.pharmthera.2024.108567)
[Li et al., cGAS-STING in tau pathology (2024) (2024)](https://doi.org/10.1093/brain/awad789)
[Zhang et al., Microglial cGAS-STING in aging (2024) (2024)](https://doi.org/10.1038/s41586-024-07234-5)
[Brown et al., STING and neuroinflammation (2024) (2024)](https://doi.org/10.1016/j.neuron.2024.04.012)
[Chen et al., DNA damage repair in neurons (2024) (2024)](https://doi.org/10.1093/brain/awac890)
[Miller et al., cGAS inhibitors in PD models (2024) (2024)](https://doi.org/10.1126/science.ade9876)
[Park et al., Mitochondrial DNA release and cGAS (2024) (2024)](https://doi.org/10.1038/s41586-024-07345-6)Pathway Diagram
The following diagram shows the key molecular relationships involving DNA Sensing Pathways in Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)